67376 Federal Register / Vol. 62, No. 247 / Wednesday, December 24, 1997 / Notices

Toxicological profile NTIS order No. CAS No.

THIOCYANATE ............................................................................................................... 000302–04–5

POTASSIUM CYANIDE .................................................................................................. 000151–50–8

CALCIUM CYANIDE ....................................................................................................... 000592–01–8

COPPER(I) CYANIDE .................................................................................................... 000544–92–3

POTASSIUM SILVER CYANIDE .................................................................................... 000506–61–6

CYANOGEN .................................................................................................................... 000460–19–5

CYANOGEN CHLORIDE ................................................................................................ 000506–77–4

6. DICHLORVOS ................................................................................................................ PB98–101124 000062–73–7

7. NICKEL (UPDATE) ........................................................................................................ PB98–101199 007440–02–0

NICKEL CHLORIDE ....................................................................................................... 007718–54–9

NICKEL OXIDE ............................................................................................................... 001313–99–1

NICKEL SULFATE .......................................................................................................... 007786–81–4

NICKEL SUBSULFIDE ................................................................................................... 012035–72–2

NICKEL ACETATE ......................................................................................................... 000373–02–4

NICKEL NITRATE ........................................................................................................... 013138–45–9

8. POLYCHLORINATED BIPHENYLS (UPDATE) ............................................................. PB98–101173 001336–36–3

AROCLOR 1016 ............................................................................................................. 012674–11–2

AROCLOR 1221 ............................................................................................................. 011104–28–2

AROCLOR 1232 ............................................................................................................. 011141–16–5

AROCLOR 1242 ............................................................................................................. 053469–21–9

AROCLOR 1248 ............................................................................................................. 012672–29–6

AROCLOR 1254 ............................................................................................................. 011097–69–1

AROCLOR 1260 ............................................................................................................. 011096–82–5

AROCLOR 1262 ............................................................................................................. 037324–23–5

AROCLOR 1268 ............................................................................................................. 011100–14–4

9. TETRACHLOROETHYLENE (UPDATE) ....................................................................... PB98–101181 000127–18–4

10. TRICHLOROETHYLENE (UPDATE) ........................................................................... PB98–101165 000079–01–6

11. VINYL CHLORIDE (UPDATE) ..................................................................................... PB98–101132 000075–01–4

Dated: December 17, 1997.

Georgi Jones,

Director, Office of Policy and External Affairs,

Agency for Toxic Substances and Disease

Registry.

[FR Doc. 97–33507 Filed 12–23–97; 8:45 am]

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Agency For Toxic Substances and

Disease Registry

[ATSDR–132]

Availability of Final Toxicological

Profiles

AGENCY: Agency for Toxic Substances

and Disease Registry (ATSDR),

Department of Health and Human

Services (HHS).

ACTION: Notice of availability.

SUMMARY: This notice announces the

availability of nine final toxicological

profiles on unregulated hazardous

substances prepared by ATSDR for the

Department of Defense.

FOR FURTHER INFORMATION CONTACT: Ms.

Loretta Norman, Division of Toxicology,

Agency for Toxic Substances and

Disease Registry, Mailstop E–29, 1600

Clifton Road, NE., Atlanta, Georgia

30333, telephone (404) 639–6322.

SUPPLEMENTARY INFORMATION: The

Superfund Amendments and

Reauthorization Act (SARA) of 1986

(Pub. L. 99–499) amended the

Comprehensive Environmental

Response, Compensation, and Liability

Act of 1980 (Superfund) or CERCLA.

Section 211 of SARA also amended

Title 10 of the U.S. Code, creating the

Defense Environmental Restoration

Program. Section 2704(a) and (b) of Title

10 of the U.S. Code directs the Secretary

of Defense to notify the Secretary of

Health and Human Services of not less

than 25 of the most commonly found,

unregulated hazardous substances at

defense facilities. The Secretary of HHS

shall take necessary steps to ensure the

timely preparation of toxicological

profiles of these substances. Each profile

includes an examination, summary and

interpretation of available toxicological

information and epidemiological

evaluations. This information and these

data are used to ascertain the levels of

significant human exposure for the

substance and the associated health

effects. The profiles include a

determination of whether adequate

information on the health effects of each

substance is available or under

development. When adequate

information is not available, in

cooperation with the National

Toxicology Program (NTP), ATSDR may

plan a program of research designed to

determine these health effects.

Notice of the availability of nine new

draft toxicological profiles for public

review and comment was published in

the Federal Register on October 18,

1994 (59 FR 52549), with notice of a 90-

day public comment period for each

profile, starting from the actual release

date. Following the close of each

comment period, chemical-specific

comments were addressed, and where

appropriate, changes were incorporated

into each profile.

The public comments, the

classification of and response to those

comments, and other data submitted in

response to the Federal Register notice

bear the docket control number ATSDR–

86. This material is available for public

inspection at the Division of Toxicology,

Agency for Toxic Substances and

Disease Registry, Building 4, Suite 2400,

Executive Park Drive, Atlanta, Georgia

(not a mailing address), between 8 a.m.

and 4:30 p.m., Monday through Friday,

except legal holidays.

Availability

This notice announces the availability

of nine final toxicological profiles for

the Department of Defense. The

following toxicological profiles are now

available through the U.S. Department

of Commerce, National Technical

Information Service (NTIS), 5285 Port

Royal Road, Springfield, Virginia 22161,

telephone 1–800–553–6847. There is a

charge for these profiles as determined

by NTIS.
Federal Register / Vol. 62, No. 247 / Wednesday, December 24, 1997 / Notices 67377

Toxicological profile NTIS order No. CAS No.

1. Di–N–OCTYLPHTHALATE ............................................................... PB98–101033 000117–84–0

2. ETHYLENE GLYCOL/ ...................................................................... PB98–101108 000107–21–1

PROPYLENE GLYCOL ..................................................................... 000057–55–6

3. HEXACHLOROETHANE .................................................................. PB98–101041 000067–72–1

4. HMX .................................................................................................. PB98–101058 002691–41–0

5. HYDRAULIC FLUIDS ....................................................................... PB98–101066 VARIOUS

6. HYDRAZINES ................................................................................... PB98–101025 000302–01–2

1,1-DIMETHYLHYDRAZINE .......................................................... 000057–14–7

1,2-DIMETHYLHYDRAZINE .......................................................... 000540–73–8

DIMETHYLHYDRAZINE ................................................................ 030260–66–3

7. MINERAL-BASED CRANKCASE OIL .............................................. PB98–101066 008002–05–9

8. TITANIUM TETRACHLORIDE .......................................................... PB98–101074 007550–45–0

9. WHITE PHOSPHORUS .................................................................... PB98–101082 007723–14–0

Dated: December 17, 1997.

Georgi Jones,

Director, Office of Policy and External Affairs,

Agency for Toxic Substances and Disease

Registry.

[FR Doc. 97–33508 Filed 12–23–97; 8:45 am]

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

National Vaccine Advisory Committee

(NVAC), Subcommittee on Future

Vaccines, Subcommittee on

Immunization Coverage, and

Subcommittee on Vaccine Safety:

Meetings

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following Federal

advisory committee meetings.

Name: National Vaccine Advisory

Committee (NVAC).

Times and Dates: 9 a.m.–2 p.m., January

12, 1998. 8:30 a.m.–1:15 p.m., January 13,

1998.

Place: Hubert H. Humphrey Building,

Room 800, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Notice: In the interest of security, the

Department has instituted stringent

procedures for entrance to the Hubert H.

Humphrey Building by non-government

employees. Thus, persons without a

government identification card should plan

to arrive at the building each day either

between 8 and 8:30 a.m. or 12:30 and 1 p.m.

so they can be escorted to the meeting.

Entrance to the meeting at other times during

the day cannot be assured.

Purpose: This committee advises and

makes recommendations to the Director of

the National Vaccine Program on matters

related to the Program responsibilities.

Matters To Be Discussed: Agenda items

will include updates on the National Vaccine

Program Office (NVPO) activities; the

National Vaccine Plan and NVAC’s role in

defining priorities for action; unmet needs

funding—past, present and future; adult

immunization: report of the workgroup; use

of non-traditional sites for adult

immunization; influenza: a growing need for

pandemic preparedness; and a discussion on

vaccines for international travel.

In addition, there will be updates on

welfare reform and effects on immunization;

moving towards a Department of Health and

Human Services’ vaccine safety action plan;

work group on philosophical exemptions—

final report; the presidential initiative on

immunization registries; global use of

critically needed vaccines—strategies to

consider. There will be reports from the

Subcommittee on Immunization Coverage,

Subcommittee on Future Vaccines, and

Subcommittee on Vaccine Safety.

Name: Subcommittee on Immunization

Coverage.

Time and Date: 2 p.m.–5 p.m., January 12,

1998.

Place: Hubert H. Humphrey Building,

Room 423A, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Purpose: This subcommittee will identify

and propose solutions that provide a

multifaceted and holistic approach to

reducing barriers that result in low

immunization coverage for children.

Matters To Be Discussed: This

subcommittee will hold a discussion on the

review of recommendations from the

document, ‘‘Strategies to Sustain

Immunization Coverage,’’ and the

finalization of those recommendations.

Name: Subcommittee on Future Vaccines.

Time and Date: 2 p.m.–5 p.m., January 12,

1998.

Place: Hubert H. Humphrey Building,

Room 405A, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Purpose: The Subcommittee on Future

Vaccines will develop policy options and

guide national activities which will lead to

accelerated development, licensure, and best

use of new vaccines in the simplest possible

immunization schedules.

Matters To Be Discussed: This

subcommittee will hold discussions

regarding the continued evaluation of

methods to remove barriers to development,

licensure and use of safe and effective new

vaccines; combination vaccines, strategic

options; and defining future vaccines policy

issues for travelers’ vaccines.

Name: Subcommittee on Vaccine Safety.

Time and Date: 2 p.m.–5 p.m., January 12,

1998.

Place: Hubert H. Humphrey Building,

Room 800, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Purpose: This subcommittee will review

issues relevant to vaccine safety and adverse

reactions to vaccines.

Matters To Be Discussed: This

subcommittee will hold discussions

regarding its goals; a report from the Task

Force on Safer Childhood Vaccines; a project

report on benefit-risk communication

curriculum development; and agenda items

for the next meeting.

Agenda items are subject to change as

priorities dictate.

Contact Person for More Information:

Felecia D. Pearson, Committee Management

Specialist, NVPO, CDC, 1600 Clifton Road,

NE, M/S D50, Atlanta, Georgia 30333,

telephone 404/639–4450.

Dated: December 19, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 97–33666 Filed 12–23–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 97D–0148]

International Conference on

Harmonisation; Guidance on

Impurities: Residual Solvents

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is publishing a

guidance entitled ‘‘Q3C Impurities: